Transthyretin (TTR)

Inotersen sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide that targets the transthyretin (TTR) RNA transcript to inhibit the production of TTR protein. This reduction in TTR levels makes Inotersen sodium a valuable tool for studying hereditary TTR amyloidosis polyneuropathy. Its mechanism of action provides insight into potential therapeutic strategies for related disorders.

Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide that targets transthyretin (TTR) mRNA, effectively inhibiting the production of both variant and wild-type TTR protein. By reducing TTR levels, Eplontersen sodium plays a crucial role in addressing conditions associated with amyloid TTR (ATTR) amyloidosis, where misfolded TTR leads to the formation of amyloid fibrils affecting the heart and peripheral nerves. This compound is pivotal for research in therapeutic strategies aimed at managing hereditary and wild-type forms of amyloidosis.

Inotersen is a 2'-O-methoxyethyl-modified antisense oligonucleotide targeting transthyretin (TTR) to inhibit its production. By binding to TTR mRNA, Inotersen promotes RNase H1-mediated degradation, leading to a decrease in both mutant and wild-type TTR synthesis in the liver. This reduction significantly mitigates amyloid fiber deposition, making Inotersen a valuable tool in research focused on hereditary transthyretin amyloidosis, including its related complications such as polyneuropathy and cardiomyopathy. Caution is advised, as high doses may lead to specific toxicities, including inflammation or tumor development in certain animal models.

Acoramidis, also known as AG10, is a selective kinetic stabilizer that targets wild-type and V122I transthyretin (TTR). It is utilized in research focused on transthyretin amyloidosis, facilitating the understanding of its molecular mechanisms and potential therapeutic strategies. Through its stabilization of TTR, Acoramidis contributes valuable insights into the treatment of amyloid-related diseases.

Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a) conjugated antisense oligonucleotide that selectively targets transthyretin (TTR) mRNA. By inhibiting the synthesis of both variant and wild-type TTR proteins, Eplontersen plays a crucial role in disrupting the misfolding of TTR, which contributes to the formation of amyloid fibrils associated with ATTR amyloidosis. This compound is valuable for research applications focused on amyloid-related diseases and exploring therapeutic strategies for TTR-related pathologies.

Acoramidis hydrochloride is a selective kinetic stabilizer of wild-type and V122I transthyretin (TTR). This compound is actively researched for its potential to inhibit the formation of amyloid fibrils associated with transthyretin amyloidosis. Its application in preclinical and clinical studies aims to further understand TTR's role in disease pathways and to develop effective therapeutic strategies.

WT-TTR Inhibitor 1 is a selective inhibitor of wild-type Transthyretin (WT-TTR), demonstrating 29.05% inhibition at a concentration of 100 μM. This compound is valuable for research applications focused on amyloidogenesis and associated diseases, including familial amyloid polyneuropathy. Its demonstrated inhibitory capacity makes it a potential tool for studying the effects of WT-TTR on protein misfolding and aggregation.

Dichlorophenyl-ABA is a potent inhibitor of transthyretin (TTR) amyloid fibril formation. It demonstrates the ability to significantly inhibit aggregate formation by over 80% in TTR L55P-expressing cells. This compound is valuable for research focused on amyloid-related disorders, particularly in understanding TTR's role in amyloidosis.

TTR Stabilizer 1 is a potent stabilizer of Transthyretin (TTR) with an EC50 value of 0.031 μM. This compound enhances TTR stability, making it an important tool for research into amyloid diseases associated with TTR misfolding. Its ability to modulate TTR functional integrity offers significant potential for studies focused on therapeutic interventions in related pathologies.

Transthyretin-IN-3 is a benzofuran analogue that selectively inhibits transthyretin (TTR) by binding to its thyroxine binding site. This compound effectively disrupts amyloid aggregation, demonstrating an IC50 value of 5.0±0.2 μM. By preventing the dissociation of TTR tetramers into unstable monomers, Transthyretin-IN-3 shows potential in research applications related to amyloid-related diseases.

Revusiran is a first-generation short interfering RNA (siRNA) that targets and inhibits transthyretin (TTR) mRNA. By reducing TTR expression, Revusiran is instrumental in studying TTR-mediated amyloidosis and its associated pathologies. This reagent serves as a valuable tool for researchers investigating the molecular mechanisms of amyloid formation and potential therapeutic interventions.

Transthyretin-IN-4 is a bivalent inhibitor targeting transthyretin (TTR) amyloidosis with a bIC50 of 0.09 µM. This compound is instrumental in researching fatal heart failure with preserved ejection fraction (HFpEF) and associated fatal arrhythmias. Its ability to modulate TTR dynamics makes it a valuable tool for investigating the pathophysiology of TTR-related diseases.

Transthyretin-IN-2 is a transthyretin (TTR) inhibitor that effectively targets TTR amyloidosis, demonstrating an IC50 value of 1.31 μM. This compound plays a crucial role in the study of TTR-related amyloid diseases, providing valuable insights into therapeutic approaches for managing amyloidosis. Researchers may utilize Transthyretin-IN-2 for investigations into the biochemical pathways of TTR misfolding and aggregation.

TTR Stabilizer L6 is a specific compound that binds to the T4 binding pocket of transthyretin (TTR), effectively preventing its dissociation into monomers. This stabilization is crucial for maintaining TTR's functional integrity, making L6 a valuable tool in the study of familial amyloid polyneuropathy. Its ability to modulate TTR behavior positions it as a promising candidate for research focused on amyloid-related diseases.